Babies Bliss Singapore: Holistic Support for Couples Trying to Conceive During the Festive Season
Helping Couples Navigate Fertility Challenges with Care and Compassion SINGAPORE, Feb. 7, 2025 /PRNewswire/ -- As the festive season approaches, many couples facing fertility challenges experience added emotional stress, making it a vulnerable time for those trying to conceive. Babies Bliss Singapore, a trusted leader in holistic fertility support, offers a compassionate, integrated approach to help couples navigate their...
GCCL Wins 2025 Asia-Pacific Customer Value Leadership Award by Frost & Sullivan
- GCCL's "One-Stop Lab Solution" sets the industry benchmark with unmatched competitiveness and a dedication to global excellence. - Continuing its growth as a globally recognized leader in clinical sample analysis, driven by customer-centric values. YONGIN, South Korea, Feb. 7, 2025 /PRNewswire/ -- GCCL(Global Clinical Central Lab), a leading Korean clinical trial...
Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects SHANGHAI, Feb. 7, 2025 /PRNewswire/ -- Today, Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. In June 2024,...
Corti’s First AId Report: Burnout levels challenge healthcare professionals’ ability to care for patients in Europe and the U.S.
Artificial Intelligence could be a lifeline but unsuccessful trials, limited opportunities, and lack of experience is holding healthcare professionals back Europe lagging behind the U.S. in terms of acceptance and adoption of AI and differences exist within the European markets U.S. healthcare professionals using AI are up to three hours every...
Stroke Detection Innovator Wellumio Enrolls First Patient in Australian Clinical Trial for ‘Axana’ 0.1T portable magnetic resonance imaging device (Portable MRI study)
"Revolutionary portable device leverages advanced magnetic resonance technology to rapidly detect acute stroke biomarkers, enabling frontline care teams to make faster, life-saving decisions within the critical 'golden hour." A Melbourne hospital images the first patient in Australia using the Wellumio Axana device, marking a milestone in advancing rapid acute stroke detection in the Emergency...
Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar...
The View From the World’s Largest Humanitarian Aid Hub – Dubai Humanitarian: Children Suffered Most From Global Crises in 2024
- Over $137m of aid distributed to 106 countries from Dubai Humanitarian aid hub used by international organisations including UNICEF, IFRC, WHO and WFP FULL RELEASE CAN BE DOWNLOADED HERE DUBAI, UAE, Feb. 6, 2025 /PRNewswire/ -- Dubai Humanitarian, the world's largest humanitarian aid hub, leading efforts to provide aid to those affected by the crisis in Gaza, has...
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (Study ID: JSKN003-301). The...
Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
HONG KONG, Feb. 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its independently developed PD-1/VEGF bispecific antibody. This clinical study, conducted in China, compares ivonescimab in combination with platinum-based chemotherapy to tislelizumab (a PD-1 inhibitor) combined...
St. Luke’s Medical Center Achieves GHA Accreditation for Medical Travel Services
PALM BEACH GARDENS, Fla., Feb. 6, 2025 /PRNewswire/ -- St. Luke's Medical Center has achieved another significant milestone, becoming the first and only hospital in the Philippines to receive accreditation from the esteemed Global Healthcare Accreditation (GHA). This outstanding accomplishment underscores the hospital's steadfast commitment to providing world-class healthcare services to both local and international patients. The...
